The Goldman Sachs Group Boosts Axon Enterprise (NASDAQ:AXON) Price Target to $441.00

Axon Enterprise (NASDAQ:AXON) had its price objective lifted by The Goldman Sachs Group from $385.00 to $441.00 in a research note issued to investors on Wednesday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

AXON has been the subject of several other reports. Northland Securities boosted their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. JMP Securities boosted their price objective on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Craig Hallum raised their target price on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Robert W. Baird lifted their target price on Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Finally, Needham & Company LLC increased their price target on Axon Enterprise from $400.00 to $525.00 and gave the company a “buy” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $382.85.

Axon Enterprise Trading Up 0.3 %

Shares of Axon Enterprise stock opened at $444.52 on Wednesday. The stock has a market capitalization of $33.55 billion, a PE ratio of 129.98, a price-to-earnings-growth ratio of 12.05 and a beta of 0.94. Axon Enterprise has a 52 week low of $199.29 and a 52 week high of $455.17. The stock has a 50 day moving average price of $396.09 and a two-hundred day moving average price of $336.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. Axon Enterprise’s revenue was up 34.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.80 EPS. As a group, equities analysts anticipate that Axon Enterprise will post 1.79 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the sale, the director now owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the sale, the director now directly owns 26,259 shares of the company’s stock, valued at $11,500,916.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Patrick W. Smith sold 80,300 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total value of $29,853,934.00. Following the transaction, the chief executive officer now directly owns 3,015,366 shares in the company, valued at $1,121,052,771.48. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 371,172 shares of company stock worth $137,000,162. 6.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AXON. Blue Trust Inc. lifted its position in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 79 shares in the last quarter. Trivant Custom Portfolio Group LLC bought a new stake in shares of Axon Enterprise during the 1st quarter valued at $31,000. Quent Capital LLC raised its stake in shares of Axon Enterprise by 1,875.0% during the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 75 shares during the period. Asset Dedication LLC bought a new position in Axon Enterprise in the 2nd quarter worth about $47,000. Finally, Friedenthal Financial bought a new position in Axon Enterprise in the 3rd quarter worth about $51,000. 79.08% of the stock is owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.